Cannabis-Dependent People Had Significantly Blunted Dopamine Release in the Brain's Reward System

PET imaging with [11C]-(+)-PHNO before and after oral amphetamine in 11 cannabis-dependent subjects (comorbidity-free, nicotine-free) and 12 healthy controls. Cannabis-dependent participants were inpatient for 5-7 days prior to scans. MRS glutamate measures were also obtained.

This is one of the most rigorous demonstrations that cannabis dependence is associated with dopaminergic deficits similar to those seen in other addictions. By excluding all comorbidities (including nicotine), the study isolated cannabis's specific contribution. The large effect sizes and the correlation with real-world cognitive and psychiatric symptoms make these findings clinically significant.

The "blunted dopamine" hypothesis of addiction proposes that chronic drug use reduces the brain's ability to release dopamine in response to rewards, driving continued use and contributing to the motivational deficits seen in dependent users. This study provides the first clean evidence that cannabis dependence fits this pattern, placing it alongside alcohol, cocaine, and opioid dependence in terms of dopaminergic impact.

Small sample size (11 per group). 5-7 days of abstinence may not be enough to determine whether deficits are permanent or reversible. The study selected severely dependent participants, so findings may not generalize to moderate or recreational users. Only male participants were included (based on abstract). The cross-sectional design cannot determine whether reduced dopamine release precedes or follows cannabis dependence.